Welcome to our dedicated page for ZIMVIE news (Ticker: ZIMV), a resource for investors and traders seeking the latest updates and insights on ZIMVIE stock.
ZimVie Inc. reports developments in its dental implant and digital dentistry business, including product launches, distribution arrangements, operating results, and corporate governance matters. The company develops, manufactures, and delivers products and solutions for dental tooth replacement and restoration, including dental implants, biomaterials, and digital workflow tools.
Recurring updates include commercial expansion in international dental markets, launches of the RealGUIDE Software Suite and Implant Concierge service, and commercial arrangements that extend access to ZimVie implant systems. Company news also includes capital-structure disclosures, stockholder voting matters, material agreements, and clinical or regulatory disclosures tied to its dental products and technology portfolio.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ZimVie Inc. (Nasdaq: ZIMV) has launched its latest educational facility, the ZimVie Institute South, in Palm Beach Gardens, Florida. This state-of-the-art center spans over 11,000 sq. ft. and is designed for hands-on dental training. It features advanced training spaces including life-like simulated patient models, a cadaver lab, and a fully integrated digital workflow incorporating 3D printing and RealGUIDE™ software.
The facility aims to enhance professional development for dental practitioners, with plans to accommodate over 1,500 dental professionals annually. ZimVie currently trains over 100,000 dental professionals worldwide through its six institutes and virtual programs. This initiative reflects ZimVie’s commitment to leading advancements in dental education and innovation.
ZimVie has launched two new dental biomaterials, the RegenerOss CC Allograft Particulate and RegenerOss Bone Graft Plug, expanding its portfolio of bone graft solutions for dental applications. These products aim to fill bony voids and assist in dental procedures, enhancing ZimVie's presence in the dental biomaterials market. The RegenerOss solutions complement ZimVie's existing Puros Allograft line, which is known for its clinical efficacy. Indraneel Kanaglekar, SVP and President of ZimVie Dental, emphasized the company’s commitment to innovation and expanding its product offerings to meet customer needs.
Founded in March 2022, ZimVie focuses on the dental and spine markets and serves customers in over 70 countries with an extensive portfolio of clinically supported products.
ZimVie Inc. (Nasdaq: ZIMV) will release its first quarter 2023 financial results on May 3, 2023, after market close. A conference call is scheduled for the same day at 4:30 p.m. Eastern Time to discuss the results. Interested participants can register in advance to listen to the call, and an archived replay will be available afterwards on the company’s investor relations website. Founded as a spin-off from Zimmer Biomet in March 2022, ZimVie specializes in the dental and spine markets, providing a range of innovative products aimed at treating spine pathologies and aiding dental procedures. With operations in over 70 countries, ZimVie aims to leverage extensive clinical evidence to support its diversified product portfolio.